clement, Author at BaseLaunch

Investors see great potential in Polyneuron

Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…

clement17.09.2020

All Portfolio news

TOLREMO Therapeutics receives additional CHF 4.7 million financing

This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…

clement19.08.2020

All Portfolio news

Alentis Therapeutics appoints Dr. Roberto Iacone

Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare…

clement19.08.2020

All Portfolio news

Versameb closes CHF 6 million seed round

Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…

clement19.08.2020

All Portfolio news

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…

clement19.08.2020

female laboratory worker looking into microscope

All Portfolio news

PharmaBiome secures CHF 1.75 million

PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…

clement19.08.2020

Scientist in a Lab Coat looking at Laboratory samples

All Features

News bulletin: CSL Behring becomes BaseLaunch partner for Phase II

We are very pleased to welcome CSL Behring, one of the largest biotech companies in the world, as a partner in BaseLaunch Phase II. Read the…

clement30.07.2020

All Interviews

Featured Interview: BaseLaunch Q&A session with Dr. Philipp Marchand

“IP rights are usually the true asset that a start-up company has.” Dr. Philipp Marchand talks with BaseLaunch and takes some questions from an audience…

clement28.07.2020

All Features

Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner

Special Report: The latest addition to the partner portfolio all the way from Asia Pacific. A warm welcome to Bridge Biotherapeutics, for which CEO, James Lee,…

clement14.07.2020

All Features

News flash: Roivant Sciences continues partnership

We welcome back Roivant Sciences with open arms for the continuation of their partnership with BaseLaunch Phase II. Sascha Bucher, Head of Global Transactions at…

clement24.06.2020

clement

Investors see great potential in Polyneuron

TOLREMO Therapeutics receives additional CHF 4.7 million financing

Alentis Therapeutics appoints Dr. Roberto Iacone

Versameb closes CHF 6 million seed round

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

PharmaBiome secures CHF 1.75 million

News bulletin: CSL Behring becomes BaseLaunch partner for Phase II

Featured Interview: BaseLaunch Q&A session with Dr. Philipp Marchand

Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner

News flash: Roivant Sciences continues partnership

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us